Increasing chemotherapy in small-cell lung cancer: From dose intensity and density to megadoses

Gino Crivellari, Silvio Monfardini, Silvia Stragliotto, Dario Marino, Savina Maria Luciana Aversa

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The hypothesis that increasing cytotoxic dose intensity will improve cancer cure rates is compelling. Although supporting evidence for this hypothesis has accrued for several tumor types, including lymphomas, breast cancer, and testicular cancers, it remains unproven. Small-cell lung cancer is extremely chemo- and radiosensitive, with a response rate of 80% achieved routinely, but few patients are cured by chemoradiotherapy. In this setting, increased cytotoxic dose intensity might improve cure rates. The finding that response rates in small-cell lung cancer correlate with received cytotoxic dose intensity merely confirms that "less is worse" and "more is better." Within conventional ranges, dose intensity can be increased with the support of hematopoietic growth factors and/or by shortening treatments intervals; however, dose intensity could be increased by only 20%-30%, and a survival advantage has not been clearly demonstrated. Given its high chemosensitivity, small-cell lung cancer was one of the first malignancies deemed suitable for increasing dose intensity and even for the use of a megadose with the support of autologous bone marrow transplantation. Some interest is emerging again due to improvements in supportive care, such as the availability of hematopoietic growth factors and peripheral blood progenitor cells.

Original languageEnglish
Pages (from-to)79-89
Number of pages11
JournalThe oncologist
Volume12
Issue number1
DOIs
Publication statusPublished - 2007

Fingerprint

Small Cell Lung Carcinoma
Drug Therapy
Intercellular Signaling Peptides and Proteins
Neoplasms
Autologous Transplantation
Testicular Neoplasms
Chemoradiotherapy
Bone Marrow Transplantation
Lymphoma
Blood Cells
Stem Cells
Breast Neoplasms
Survival
Therapeutics

Keywords

  • Dose density
  • Dose intensity
  • Megadose
  • Small-cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Increasing chemotherapy in small-cell lung cancer : From dose intensity and density to megadoses. / Crivellari, Gino; Monfardini, Silvio; Stragliotto, Silvia; Marino, Dario; Aversa, Savina Maria Luciana.

In: The oncologist, Vol. 12, No. 1, 2007, p. 79-89.

Research output: Contribution to journalArticle

Crivellari, Gino ; Monfardini, Silvio ; Stragliotto, Silvia ; Marino, Dario ; Aversa, Savina Maria Luciana. / Increasing chemotherapy in small-cell lung cancer : From dose intensity and density to megadoses. In: The oncologist. 2007 ; Vol. 12, No. 1. pp. 79-89.
@article{fb8007a9c0b247f0a4c17e9db9a6011f,
title = "Increasing chemotherapy in small-cell lung cancer: From dose intensity and density to megadoses",
abstract = "The hypothesis that increasing cytotoxic dose intensity will improve cancer cure rates is compelling. Although supporting evidence for this hypothesis has accrued for several tumor types, including lymphomas, breast cancer, and testicular cancers, it remains unproven. Small-cell lung cancer is extremely chemo- and radiosensitive, with a response rate of 80{\%} achieved routinely, but few patients are cured by chemoradiotherapy. In this setting, increased cytotoxic dose intensity might improve cure rates. The finding that response rates in small-cell lung cancer correlate with received cytotoxic dose intensity merely confirms that {"}less is worse{"} and {"}more is better.{"} Within conventional ranges, dose intensity can be increased with the support of hematopoietic growth factors and/or by shortening treatments intervals; however, dose intensity could be increased by only 20{\%}-30{\%}, and a survival advantage has not been clearly demonstrated. Given its high chemosensitivity, small-cell lung cancer was one of the first malignancies deemed suitable for increasing dose intensity and even for the use of a megadose with the support of autologous bone marrow transplantation. Some interest is emerging again due to improvements in supportive care, such as the availability of hematopoietic growth factors and peripheral blood progenitor cells.",
keywords = "Dose density, Dose intensity, Megadose, Small-cell lung cancer",
author = "Gino Crivellari and Silvio Monfardini and Silvia Stragliotto and Dario Marino and Aversa, {Savina Maria Luciana}",
year = "2007",
doi = "10.1634/theoncologist.12-1-79",
language = "English",
volume = "12",
pages = "79--89",
journal = "Oncologist",
issn = "1083-7159",
publisher = "Wiley Blackwell",
number = "1",

}

TY - JOUR

T1 - Increasing chemotherapy in small-cell lung cancer

T2 - From dose intensity and density to megadoses

AU - Crivellari, Gino

AU - Monfardini, Silvio

AU - Stragliotto, Silvia

AU - Marino, Dario

AU - Aversa, Savina Maria Luciana

PY - 2007

Y1 - 2007

N2 - The hypothesis that increasing cytotoxic dose intensity will improve cancer cure rates is compelling. Although supporting evidence for this hypothesis has accrued for several tumor types, including lymphomas, breast cancer, and testicular cancers, it remains unproven. Small-cell lung cancer is extremely chemo- and radiosensitive, with a response rate of 80% achieved routinely, but few patients are cured by chemoradiotherapy. In this setting, increased cytotoxic dose intensity might improve cure rates. The finding that response rates in small-cell lung cancer correlate with received cytotoxic dose intensity merely confirms that "less is worse" and "more is better." Within conventional ranges, dose intensity can be increased with the support of hematopoietic growth factors and/or by shortening treatments intervals; however, dose intensity could be increased by only 20%-30%, and a survival advantage has not been clearly demonstrated. Given its high chemosensitivity, small-cell lung cancer was one of the first malignancies deemed suitable for increasing dose intensity and even for the use of a megadose with the support of autologous bone marrow transplantation. Some interest is emerging again due to improvements in supportive care, such as the availability of hematopoietic growth factors and peripheral blood progenitor cells.

AB - The hypothesis that increasing cytotoxic dose intensity will improve cancer cure rates is compelling. Although supporting evidence for this hypothesis has accrued for several tumor types, including lymphomas, breast cancer, and testicular cancers, it remains unproven. Small-cell lung cancer is extremely chemo- and radiosensitive, with a response rate of 80% achieved routinely, but few patients are cured by chemoradiotherapy. In this setting, increased cytotoxic dose intensity might improve cure rates. The finding that response rates in small-cell lung cancer correlate with received cytotoxic dose intensity merely confirms that "less is worse" and "more is better." Within conventional ranges, dose intensity can be increased with the support of hematopoietic growth factors and/or by shortening treatments intervals; however, dose intensity could be increased by only 20%-30%, and a survival advantage has not been clearly demonstrated. Given its high chemosensitivity, small-cell lung cancer was one of the first malignancies deemed suitable for increasing dose intensity and even for the use of a megadose with the support of autologous bone marrow transplantation. Some interest is emerging again due to improvements in supportive care, such as the availability of hematopoietic growth factors and peripheral blood progenitor cells.

KW - Dose density

KW - Dose intensity

KW - Megadose

KW - Small-cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=33846416249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846416249&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.12-1-79

DO - 10.1634/theoncologist.12-1-79

M3 - Article

C2 - 17227903

AN - SCOPUS:33846416249

VL - 12

SP - 79

EP - 89

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 1

ER -